TRi-1

Research use only, not for human use.

TRi-1 is irreversible inhibitor of?cytosolic thioredoxin reductase 1 (TXNRD1) with an?IC50?of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy.

TRi-1 is irreversible inhibitor of?cytosolic thioredoxin reductase 1 (TXNRD1) with an?IC50?of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy.

Western Blot Analysis Cell Line:FaDu cellsConcentration:0.679 and 6.79 μM Incubation Time:6 hResult:Efficiently activated JNK and p38 phosphorylation. Cell Cytotoxicity Assay Cell Line:Leukemia, non-small cell lung, CNS, colon, melanoma, ovarian, renal, prostate and breast cancer cells Concentration:10 nM-100 μM Incubation Time:48 h Result:Displayed potency against every cell line tested, with an average growth inhibition to 50% (GI50) of 6.31 μM.

Animal Model:SCID mice bearing established human FaDu cell xenograftsDosage:10 mg/kg Administration:Intravenous injection, twice a day for 4 days Result:Resulted in decreased tumor growth compared to vehicle controls within four days with no signs of overt toxicity or changes in mouse weight relative to vehicle control.Animal Model:PyMT-MMTV mice that spontaneously develop malignant breast cancer tumors.Dosage:5 mg/kg Administration: Intraperitoneal injection, twice a week for 3 weeks Result:Impaired tumor growth, significantly reduced tumor volumes.

——

Others

Other Targets

TXNRD1

——

——

246020-68-8

328.72

C12H9ClN2O5S

>98% (HPLC)

DMSO:62.5 mg/mL?(190.13 mM)

COc1ccc(c(n1)S(=O)(=O)c1ccc(Cl)cc1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years